Reviewing Antiviral Research against Viruses Causing Human Diseases - a Structure-Guided Approach

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388963%3A_____%2F22%3A00557951" target="_blank" >RIV/61388963:_____/22:00557951 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.2174/1874467214666210804152836" target="_blank" >https://doi.org/10.2174/1874467214666210804152836</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2174/1874467214666210804152836" target="_blank" >10.2174/1874467214666210804152836</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Reviewing Antiviral Research against Viruses Causing Human Diseases - a Structure-Guided Approach

Popis výsledku v původním jazyce

The smallest of all the pathogens, viruses, have continuously been the foremost strange microorganisms. Viral infections can cause extreme sicknesses as evidenced by the HIV/AIDS widespread or the later Ebola or Zika episodes. Apprehensive framework distortions are also regularly observed as consequences of numerous viral infections. Besides, numerous viral infections are of oncoviruses, which can trigger different types of cancer. Nearly every year, a modern infectious species emerges, debilitating the world population with an annihilating episode. Subsequently, there is a need to create antivirals to combat such rising infections. From the discovery of the antiviral drug Idoxuridine in 1962 to the revelation of Baloxavir marboxil (Xofluza) that was approved by the FDA in 2018, the whole process and criteria of creating antivirals have changed significantly. In this article, different auxiliary science strategies are described that can serve as a referral for therapeutic innovation.

Název v anglickém jazyce

Reviewing Antiviral Research against Viruses Causing Human Diseases - a Structure-Guided Approach

Popis výsledku anglicky

The smallest of all the pathogens, viruses, have continuously been the foremost strange microorganisms. Viral infections can cause extreme sicknesses as evidenced by the HIV/AIDS widespread or the later Ebola or Zika episodes. Apprehensive framework distortions are also regularly observed as consequences of numerous viral infections. Besides, numerous viral infections are of oncoviruses, which can trigger different types of cancer. Nearly every year, a modern infectious species emerges, debilitating the world population with an annihilating episode. Subsequently, there is a need to create antivirals to combat such rising infections. From the discovery of the antiviral drug Idoxuridine in 1962 to the revelation of Baloxavir marboxil (Xofluza) that was approved by the FDA in 2018, the whole process and criteria of creating antivirals have changed significantly. In this article, different auxiliary science strategies are described that can serve as a referral for therapeutic innovation.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10607 - Virology

Projekt

<a href="/cs/project/EF16_019%2F0000729" target="_blank" >EF16_019/0000729: Chemická biologie pro vývoj nových terapií</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Current Molecular Pharmacology

ISSN

1874-4672

e-ISSN

1874-4702

Svazek periodika

15

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

AE - Spojené arabské emiráty

Počet stran výsledku

32

Strana od-do

306-337

Kód UT WoS článku

000819380800004

EID výsledku v databázi Scopus

2-s2.0-85130861968